FUSN vs. TWST, RXRX, SANA, DNA, BEAM, NMRA, INBX, ADMA, KYMR, and VCEL
Should you be buying Fusion Pharmaceuticals stock or one of its competitors? The main competitors of Fusion Pharmaceuticals include Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Neumora Therapeutics (NMRA), Inhibrx (INBX), ADMA Biologics (ADMA), Kymera Therapeutics (KYMR), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
In the previous week, Twist Bioscience had 2 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 7 mentions for Twist Bioscience and 5 mentions for Fusion Pharmaceuticals. Fusion Pharmaceuticals' average media sentiment score of 0.60 beat Twist Bioscience's score of 0.33 indicating that Twist Bioscience is being referred to more favorably in the media.
Fusion Pharmaceuticals has lower revenue, but higher earnings than Twist Bioscience. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
72.9% of Fusion Pharmaceuticals shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by company insiders. Comparatively, 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Twist Bioscience has a net margin of -78.44% compared to Twist Bioscience's net margin of -4,136.55%. Fusion Pharmaceuticals' return on equity of -32.16% beat Twist Bioscience's return on equity.
Twist Bioscience has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Fusion Pharmaceuticals has a beta of -0.72, suggesting that its stock price is 172% less volatile than the S&P 500.
Twist Bioscience presently has a consensus price target of $36.40, suggesting a potential upside of 15.41%. Fusion Pharmaceuticals has a consensus price target of $20.25, suggesting a potential downside of 5.46%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Twist Bioscience is more favorable than Fusion Pharmaceuticals.
Twist Bioscience received 44 more outperform votes than Fusion Pharmaceuticals when rated by MarketBeat users. However, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 55.56% of users gave Twist Bioscience an outperform vote.
Summary
Twist Bioscience beats Fusion Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Fusion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FUSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Pharmaceuticals Competitors List
Related Companies and Tools
